Author:
Dietel M.,Tannapfel A.,Baretton G.,Kreipe H.,Kloor M.,Gabbert H.,Kirchner T.
Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Amado RG, Wolf M, Freeman D et al. (2007) Wild-type KRAS is required for Panitumumab efficacy in patients with metastatic colorectal cancer: results from a randomized, controlled trial. EJC [Suppl] 5: 7LB
2. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. (2007) Oncogenic activation of the RAS/RAF signalling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643–2648
3. Berlin J, Van Cutsem E, Peeters M et al. (2006) Safety and efficacy of Panitumumab monotherapy in the treatment of metastatic colorectal cancer (mCRC) summary of results across clinical studies. Ann Oncol 17 [Suppl] 9:ix114, Abstract 326O
4. De Roock W, Piessevaux H, De Schutter J et al. (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol (in press)
5. Freeman D, Juan T, Meropol NJ et al. (2007) Association of somatic KRAS gene mutations and clinical outcome in patients with metastatic colorectal cancer receiving Panitumumab monotherapy. EJC [Suppl] 5: 3014
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献